Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

被引:9
|
作者
Tong, Yan [1 ]
Huang, Jian Qing [1 ]
Chen, Yang [1 ]
Tu, Mei [1 ]
Wang, Wei [1 ]
机构
[1] Fujian Med Univ, Longyan Affiliated Hosp 1, Longyan, Fujian, Peoples R China
关键词
liraglutide; sitagliptin; bowel preparation quality; gastrointestinal discomfort; gastrointestinal motility; DOSE POLYETHYLENE-GLYCOL; GLUCOSE; COLONOSCOPY; EXENATIDE; SUPERIOR; MOTILITY; TRANSIT;
D O I
10.3389/fphar.2023.1176206
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM). Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety. Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025). Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    I. Raz
    M. Hanefeld
    L. Xu
    C. Caria
    D. Williams-Herman
    H. Khatami
    Diabetologia, 2006, 49 : 2564 - 2571
  • [42] NEPHROPATHY EVOLUTION IS PREVENTED BY THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR, SITAGLIPTIN, IN A RAT MODEL OF TYPE 2 DIABETES
    Mega, Cristina
    Reis, Flavio
    de Lemos, Edite Teixeira
    Vala, Helena
    Fernandes, Rosa
    Oliveira, Jorge
    Teixeira, Frederico
    Reis, Flavio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 160 - 160
  • [43] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    Raz, I.
    Hanefeld, M.
    Xu, L.
    Caria, C.
    Williams-Herman, D.
    Khatami, H.
    DIABETOLOGIA, 2006, 49 (11) : 2564 - 2571
  • [44] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    Aschner, Pablo
    Kipnes, Mark S.
    Lunceford, Jared K.
    Sanchez, Matilde
    Mickel, Carolyn
    Williams-Herman, Debora E.
    DIABETES CARE, 2006, 29 (12) : 2632 - 2637
  • [45] The Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Suppresses Mouse Colon Tumorigenesis in Type 2 Diabetes Mice
    Yorifuji, Naoki
    Inoue, Takuya
    Fujiwara, Kaori
    Iguchi, Munetaka
    Kojima, Yuichi
    Okada, Toshihiko
    Kakimoto, Kazuki
    Nouda, Sadaharu
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2015, 148 (04) : S577 - S577
  • [46] Suppression of Food Intake by Glucagon-Like Peptide-1 Receptor Agonists: Relative Potencies and Role of Dipeptidyl Peptidase-4
    Jessen, Lene
    Aulinger, Benedikt A.
    Hassel, Jonathan L.
    Roy, Kyle J.
    Smith, Eric P.
    Greer, Todd M.
    Woods, Stephen C.
    Seeley, Randy J.
    D'Alessio, David A.
    ENDOCRINOLOGY, 2012, 153 (12) : 5735 - 5745
  • [47] Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
    Patel, Kershaw, V
    Sarraju, Ashish
    Neeland, Ian J.
    McGuire, Darren K.
    CURRENT CARDIOLOGY REPORTS, 2020, 22 (10)
  • [48] Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
    Kershaw V. Patel
    Ashish Sarraju
    Ian J. Neeland
    Darren K. McGuire
    Current Cardiology Reports, 2020, 22
  • [49] Canagliflozin added on to dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 agonists with or without other antihyperglycaemic agents in type 2 diabetes mellitus
    Meininger, G.
    Wysham, C.
    Woo, V.
    Mathieu, C.
    Capuano, G.
    Alba, M.
    Desai, M.
    DIABETOLOGIA, 2013, 56 : S373 - S373
  • [50] Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management
    Kyriakidou, Artemis
    Koufakis, Theocharis
    Goulis, Dimitrios G.
    Vasilopoulos, Yiannis
    Zebekakis, Pantelis
    Kotsa, Kalliopi
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (08) : 1025 - 1034